Company Description
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies.
The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 6, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 483 |
| CEO | John Evans |
Contact Details
Address: 238 Main Street Cambridge, Massachusetts 02142 United States | |
| Phone | 857 327 8775 |
| Website | beamtx.com |
Stock Details
| Ticker Symbol | BEAM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0000789073 |
| CUSIP Number | 07373V105 |
| ISIN Number | US07373V1052 |
| Employer ID | 13-3295276 |
| SIC Code | 2080 |
Key Executives
| Name | Position |
|---|---|
| John M. Evans M.B.A. | Chief Executive Officer and Director |
| Dr. Giuseppe Ciaramella Ph.D. | President |
| Sravan Kumar Emany | Chief Financial Officer |
| Dr. Christine P. Bellon J.D., Ph.D. | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. Amy Simon M.D. | Chief Medical Officer |
| Dr. Feng Zhang Ph.D. | Co-Founder |
| Dr. David R. Liu Ph.D. | Co-Founder |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Dr. Manmohan Singh Ph.D. | Chief Technology Officer |
| Dr. Gopi Shanker Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2014 | NO ACT | Filing |
| May 12, 2014 | NO ACT | Filing |
| May 12, 2014 | NO ACT | Filing |
| May 12, 2014 | NO ACT | Filing |
| May 12, 2014 | 15-12B | Securities registration termination |
| May 12, 2014 | 15-12B | Securities registration termination |
| May 2, 2014 | 25 | Filing |
| Apr 30, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 30, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 30, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |